Organization Overview
Alternative names
aflibercept (zaltrap) (2 trials)
anastrozole (arimidex) (2 trials)
atezolizumab (tecentriq) (1 trial)
bacille calmette-guerin (1 trial)
bevacizumab (avastin) (9 trials)
capecitabine (xeloda) (7 trials)
carboplatin (paraplatin) (2 trials)
celecoxib (celebrex) (1 trial)
doxorubicin (Doxil) (16 trials)
epirubicin (ellence) (5 trials)
exemestane (aromasin) (3 trials)
fam-trastuzumab deruxtecan-nxki (Enhertu) (1 trial)
filgrastim (neupogen) (1 trial)
fluorouracil (efudex) (15 trials)
gemcitabine (gemzar) (3 trials)
levamisole (ergamisol) (1 trial)
methanedichlorodiphosphonic acid (1 trial)
octreotide (sandostatin) (1 trial)
oxaliplatin (eloxatin) (11 trials)
paclitaxel (taxol) (13 trials)
Adenocarcinoma (Phase 3)
Breast Neoplasms (Phase 3)
Carcinoma (Phase 3)
Carcinoma, Ductal (Phase 3)
Carcinoma in Situ (Phase 3)
Carcinoma, Intraductal, Noninfiltrating (Phase 3)
Cardiovascular Diseases (Phase 3)
Colonic Neoplasms (Phase 3)
Colorectal Neoplasms (Phase 3)
Coronary Disease (Phase 3)
Heart Diseases (Phase 3)
Ischemia (Phase 3)
Myocardial Ischemia (Phase 3)
Neoplasm Metastasis (Phase 3)
Neoplasm, Residual (Phase 3)
Neoplasms (Phase 3)
Precancerous Conditions (Phase 3)
Rectal Neoplasms (Phase 3)
Triple Negative Breast Neoplasms (Phase 3)